Neuland Laboratories Limited (NEULANDLAB) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹20,320 (+2.44% day change)
Key ratios
- P/E ratio
- 71.62
- P/B ratio
- 8.23
- ROE (%)
- 19.42
- ROCE (%)
- 21.75
- Debt/Equity
- 0.16
- Dividend yield (%)
- 0.1
- Market cap (₹ Cr)
- 26,070.33
Forensic checks
Piotroski F-Score: 6/9 · Altman Z-Score: 9.45 · Beneish M-Score: -2.01
InvestSights quality score
69.3/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Full-year capex: guided 250Rs Cr, delivered 397.13Rs Cr (FY26) — exceeded guidance
- New CMS molecule commercialisations: guided 1count, delivered 1count (FY26) — met guidance
Latest earnings call (Q2 FY27)
AI summary: The most important signal is that Neuland’s underlying opportunity pipeline appears strong, but the earnings conversion remains highly dependent on a few commercial CMS shipments while the peptide investment is still pre-ramp. Management called FY27 RFP activity the “strongest to date,” cited expanding big-pharma engagement and maintained growth expectations for FY27 and…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.